Double maintains 3 strategies that include NVCR - NovoCure Ltd.
Current Value
$17.701 Year Return
Current Value
$17.701 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KNOP | -<0.01% | $222.25M | +12.70% | 1.61% |
CLX | 0.01% | $16.13B | -0.30% | 3.72% |
ULS | -0.07% | $14.24B | +68.81% | 0.71% |
D | 0.11% | $47.47B | +5.94% | 4.77% |
PPC | 0.12% | $11.66B | +55.46% | 0.00% |
QNTM | 0.12% | $28.10M | -47.59% | 0.00% |
LMT | 0.13% | $110.22B | +0.72% | 2.75% |
NEE | -0.18% | $137.80B | -11.13% | 3.15% |
PEP | 0.21% | $178.40B | -27.42% | 4.19% |
SAND | -0.22% | $2.50B | +47.66% | 0.66% |
QD | 0.24% | $291.40M | +61.05% | 0.00% |
GO | 0.28% | $1.32B | -40.49% | 0.00% |
RILY | 0.45% | $89.20M | -90.41% | 17.36% |
CHE | -0.52% | $8.21B | +1.10% | 0.34% |
BULL | 0.55% | $6.23B | +21.84% | 0.00% |
NI | 0.59% | $18.12B | +37.11% | 2.81% |
FATBB | -0.60% | $46.73M | -22.20% | 10.68% |
ASPS | 0.66% | $72.70M | -50.60% | 0.00% |
BHC | 0.70% | $1.66B | -29.13% | 0.00% |
AEE | -0.71% | $26.39B | +33.43% | 2.83% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRSP | 45.95% | $3.24B | -32.66% | 0.00% |
SCVL | 42.97% | $533.24M | -46.24% | 2.94% |
BEAM | 42.54% | $1.73B | -28.20% | 0.00% |
ROKU | 42.07% | $10.23B | +24.15% | 0.00% |
PTCT | 41.16% | $3.61B | +22.60% | 0.00% |
COHU | 41.08% | $803.57M | -44.33% | 0.00% |
KN | 40.74% | $1.43B | -5.78% | 0.00% |
AIN | 40.62% | $1.99B | -25.73% | 1.64% |
RXRX | 40.42% | $1.68B | -54.10% | 0.00% |
DAN | 39.81% | $2.36B | +19.15% | 2.57% |
USNA | 39.21% | $559.81M | -37.14% | 0.00% |
SLAB | 38.98% | $4.00B | -1.18% | 0.00% |
TWST | 38.79% | $1.69B | -31.91% | 0.00% |
KYMR | 38.65% | $1.96B | -11.89% | 0.00% |
DBI | 38.62% | $162.40M | -63.97% | 6.31% |
TECH | 38.47% | $7.42B | -41.15% | 0.69% |
GIII | 38.13% | $1.19B | -1.79% | 0.00% |
AZTA | 38.05% | $1.28B | -44.24% | 0.00% |
CTS | 37.94% | $1.21B | -22.56% | 0.40% |
RVTY | 37.91% | $10.66B | -19.13% | 0.32% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -17.65% | $23.92B | +26.61% | 1.07% |
MO | -14.48% | $99.89B | +29.93% | 6.77% |
CME | -12.35% | $101.62B | +32.97% | 3.72% |
PM | -12.01% | $272.75B | +75.85% | 3.04% |
ED | -11.83% | $37.26B | +10.17% | 3.23% |
AQB | -11.62% | $3.27M | -54.75% | 0.00% |
T | -11.44% | $195.94B | +55.87% | 4.05% |
STG | -11.14% | $26.51M | -45.13% | 0.00% |
EXC | -10.67% | $43.83B | +17.26% | 3.57% |
AEP | -10.46% | $54.38B | +14.02% | 3.57% |
DUK | -9.79% | $89.83B | +13.54% | 3.59% |
FMTO | -8.89% | $42.10M | -99.95% | 0.00% |
SO | -8.25% | $97.64B | +15.12% | 3.24% |
ETR | -7.46% | $35.01B | +48.59% | 4.30% |
VSTA | -7.17% | $320.81M | +14.29% | 0.00% |
GFI | -7.13% | $19.73B | +39.67% | 2.43% |
VHC | -7.04% | $33.82M | +73.48% | 0.00% |
PBA | -6.67% | $21.58B | +2.43% | 5.33% |
KMB | -6.67% | $46.37B | +6.00% | 3.51% |
FMX | -6.47% | $21.80B | -8.70% | 4.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 47.18% | $920.94M | 0.75% |
GNOM | 45.97% | $42.14M | 0.5% |
XHE | 44.40% | $173.10M | 0.35% |
IBB | 40.64% | $5.41B | 0.45% |
ARKK | 40.48% | $5.70B | 0.75% |
PBE | 40.31% | $224.25M | 0.58% |
IWC | 40.14% | $784.94M | 0.6% |
RZV | 40.10% | $200.05M | 0.35% |
CALF | 39.94% | $4.43B | 0.59% |
XBI | 39.71% | $5.19B | 0.35% |
GSSC | 39.42% | $536.37M | 0.2% |
EES | 39.31% | $584.80M | 0.38% |
SLYV | 39.30% | $3.73B | 0.15% |
IJS | 39.22% | $6.19B | 0.18% |
VIOO | 39.09% | $2.87B | 0.1% |
IJR | 38.95% | $78.59B | 0.06% |
FYX | 38.93% | $812.27M | 0.6% |
IWM | 38.93% | $65.60B | 0.19% |
SPSM | 38.88% | $11.09B | 0.03% |
VTWO | 38.84% | $12.14B | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IAU | -0.01% | $45.61B | 0.25% |
SGOL | 0.03% | $5.02B | 0.17% |
GLD | 0.04% | $96.44B | 0.4% |
AAAU | 0.08% | $1.46B | 0.18% |
CANE | 0.09% | $10.30M | 0.29% |
OUNZ | 0.10% | $1.66B | 0.25% |
BAR | -0.15% | $1.11B | 0.1749% |
UNG | 0.22% | $349.65M | 1.06% |
GLDM | -0.23% | $14.48B | 0.1% |
COMT | 0.26% | $597.99M | 0.48% |
USL | 0.26% | $40.94M | 0.85% |
IBTL | 0.38% | $369.48M | 0.07% |
SHV | -0.39% | $20.82B | 0.15% |
NEAR | -0.39% | $3.28B | 0.25% |
SPTI | -0.45% | $8.77B | 0.03% |
SMMU | 0.49% | $830.50M | 0.35% |
SGOV | 0.49% | $46.65B | 0.09% |
IBTM | 0.51% | $317.33M | 0.07% |
DFNM | -0.52% | $1.54B | 0.17% |
WEAT | -0.56% | $121.36M | 0.28% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -33.16% | $360.65M | 1.43% |
VIXY | -25.77% | $126.83M | 0.85% |
TAIL | -21.95% | $118.71M | 0.59% |
IVOL | -19.11% | $355.73M | 1.02% |
FXY | -12.66% | $857.57M | 0.4% |
UDN | -10.75% | $138.93M | 0.78% |
SHYM | -9.58% | $323.08M | 0.35% |
LDUR | -8.83% | $909.54M | 0.5% |
FXE | -8.77% | $520.10M | 0.4% |
SPTS | -8.45% | $5.74B | 0.03% |
CTA | -7.34% | $1.08B | 0.76% |
FLMI | -7.13% | $669.33M | 0.3% |
UTWO | -6.75% | $384.90M | 0.15% |
STPZ | -6.73% | $453.40M | 0.2% |
IBTH | -6.67% | $1.54B | 0.07% |
ULST | -6.64% | $638.58M | 0.2% |
JMST | -6.59% | $3.71B | 0.18% |
VGSH | -5.67% | $22.37B | 0.03% |
SCHO | -5.60% | $10.87B | 0.03% |
BWX | -5.00% | $1.43B | 0.35% |
SeekingAlpha
NovoCure Limited: Profitability Remains Elusive
Yahoo
Scientists are testing electric fields and pulses against a range of diseases including rheumatoid arthritis and brain cancer.
Yahoo
The mean of analysts' price targets for NovoCure (NVCR) points to a 105.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Yahoo
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo
Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%. The medical technology company reported solid first-quarter results.
Yahoo
Thursday morning NovoCure (NASDAQ: NVCR) published its first set of quarterly results for 2025, and they pleased more than a few investors. For the first quarter, NovoCure recorded net revenue that was just shy of $155 million. Compounding that, the biotech managed to narrow its generally accepted accounting principles (GAAP) net loss by roughly the same percentage; it landed at $34.4 million ($0.31 per share) against the Q1 2024 shortfall of $38.8 million.